| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/17/2002 | WO2002003976A2 Combinations of bisphosphonates, estrogenic agents and optionally estrogens |
| 01/17/2002 | WO2002003961A1 Microspheres and adjuvants for dna vaccine delivery |
| 01/17/2002 | WO2002003957A2 Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same |
| 01/17/2002 | WO2002003912A2 Novel c-4 substituted retinoids |
| 01/17/2002 | WO2002003910A2 Antibacterial, antioxidant, immunomoduling and anticancerogenic preparation and method for using said preparation |
| 01/17/2002 | WO2002003871A1 Use of a liquid medicament in surgical high pressure liquid jet devices |
| 01/17/2002 | WO2001072962A3 Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 01/17/2002 | WO2001062786A3 Tlp peptides and dna sequences coding the same |
| 01/17/2002 | WO2001059067A3 A group of anti-cancer compounds with specific structure and their production method |
| 01/17/2002 | WO2001054678A3 Combination therapy for cancer |
| 01/17/2002 | WO2001054672A3 Closure of bacterial ghosts |
| 01/17/2002 | WO2001052791A3 Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents |
| 01/17/2002 | WO2001047950A3 Basolateral sorting signal based on scf peptide and inhibitors thereof |
| 01/17/2002 | WO2001047922A3 Azaindoles |
| 01/17/2002 | WO2001047543A3 Activation and inhibition of the immune system |
| 01/17/2002 | WO2001046228A3 Nucleic acid vaccination |
| 01/17/2002 | WO2001044448A3 Human oxidoreductase proteins |
| 01/17/2002 | WO2001044291A3 Polynucleotid encoding the rg1 polypeptide |
| 01/17/2002 | WO2001044235A3 Agents and methods for the treatment of proliferative diseases |
| 01/17/2002 | WO2001041782A3 Method for administering a cytokine to the central nervous system and the lymphatic system |
| 01/17/2002 | WO2001040446A3 Pour-on formulations |
| 01/17/2002 | WO2001038878A3 Pin1 as a marker for abnormal cell growth |
| 01/17/2002 | WO2001038303A3 Vitamin d analogues |
| 01/17/2002 | WO2001036461A3 Compositions and methods for regulating tumor-associated antigen expression |
| 01/17/2002 | WO2001032706A3 Novel human transporter proteins and polynucleotides encoding the same |
| 01/17/2002 | WO2001032696A3 Traf family proteins |
| 01/17/2002 | WO2001031051A3 Antisense modulation of protein kinase c-theta expression |
| 01/17/2002 | WO2001030362A3 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 01/17/2002 | WO2001029192A3 Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses |
| 01/17/2002 | WO2001027290A3 Aortic carboxypeptidase-like protein and nucleic acids encoding same |
| 01/17/2002 | WO2001022972A3 Immunostimulatory nucleic acids |
| 01/17/2002 | WO2001021589A3 Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof |
| 01/17/2002 | WO2001019407A3 Taxane prodrugs |
| 01/17/2002 | WO2001019406A3 Amphiphilic prodrugs |
| 01/17/2002 | WO2001013117A3 Proteins, genes and their use for diagnosis and treatment of breast cancer |
| 01/17/2002 | WO2001012598A3 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 01/17/2002 | WO2001010468A3 Drug-carrier complexes and methods of use thereof |
| 01/17/2002 | WO2001007471A3 Cell cycle and proliferation proteins |
| 01/17/2002 | WO2001007087A3 Enzyme catalyzed anti-infective therapeutic agents |
| 01/17/2002 | WO2000078953A3 Human transport proteins |
| 01/17/2002 | WO2000078952A3 Human rna metabolism proteins (rmep) |
| 01/17/2002 | WO2000060077A3 Compounds for therapy and diagnosis of lung cancer and methods for their use |
| 01/17/2002 | WO1999051284A3 Non-covalent bioconjugates useful for diagnosis and therapy |
| 01/17/2002 | US20020007173 Method of inducing a CTL response |
| 01/17/2002 | US20020007066 For treatment/prevention of infection of herpes simplex virus, varicella zoster virus, human cytomegalovirus, or epstein-Barr virus; enzyme inhibitors |
| 01/17/2002 | US20020007060 Enzyme inhibitors; connective tissue cells; antiarthritic agents; anticarcinogenic agents |
| 01/17/2002 | US20020007046 Polypeptides for use in the diagnosis, prevention and treatment of cancer and immunological defects |
| 01/17/2002 | US20020006957 Method for the synthesis of compounds of formula I and their uses thereof |
| 01/17/2002 | US20020006952 Kinase inhibitors; anticancer agents |
| 01/17/2002 | US20020006951 Solid-state form of celecoxib having enhanced bioavailability |
| 01/17/2002 | US20020006946 Obesity, antidiabetic agents, cardiovascular disorders |
| 01/17/2002 | US20020006945 Immunology diseases |
| 01/17/2002 | US20020006941 p53 inhibitors and therapeutic use of the same |
| 01/17/2002 | US20020006936 Anticancer agents; restenosis |
| 01/17/2002 | US20020006918 Prostate cancer |
| 01/17/2002 | US20020006917 Method of locking 1alpha-OH of vitamin D compounds in axial orientation |
| 01/17/2002 | US20020006913 Maintenance of Dna; reduce damage |
| 01/17/2002 | US20020006903 Genetic engineering |
| 01/17/2002 | US20020006900 Colon cancer KH-1 and N3 antigens |
| 01/17/2002 | US20020006898 Trimethyl lock based tetrapartate prodrugs |
| 01/17/2002 | US20020006654 Isolated cathepsin L type cysteine proteases and reducing intercorneocyte cohesion/promoting desquamation therewith |
| 01/17/2002 | US20020006653 Nucleotide sequences coding enzymatic polypeptide; for use in the treatment of cancers, nervous system, cardiovascular, brain, prostatic and muscle disorder |
| 01/17/2002 | US20020006640 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 01/17/2002 | US20020006630 Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers |
| 01/17/2002 | US20020006432 Bifidobacterium in the treatment of inflammatory disease |
| 01/17/2002 | US20020006413 Stimulating an immune response in a patient having an adenocarcinoma, comprising administering to such patient one or more allogenic tumor cells selected from SW620 cell, COLO 205 cell, and SW403 cell |
| 01/17/2002 | US20020006404 Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| 01/17/2002 | US20020006391 Genetic engineering |
| 01/17/2002 | DE10031955A1 Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel Curcumin derivatives with respect to curcumin improved water solubility and pharmaceutical compositions containing them |
| 01/17/2002 | DE10031651A1 Extrakte aus Sophora-Arten, Verfahren zu ihrer Herstellung und Verwendung Extracts of Sophora species, processes for their preparation and use |
| 01/17/2002 | DE10031650A1 Verwendung von Extrakten aus Sophora flavescens oder Sophora subprostrata zur Prophylaxe und Therapie von Krankheitszuständen, die durch einen Mangel an Östrogenen oder durch andere hormonelle Dysregulationen verursacht werden The use of extracts from Sophora flavescens or Sophora subprostrata for the prophylaxis and treatment of pathological conditions caused by estrogen deficiency or by other hormonal dysregulation |
| 01/17/2002 | CA2415919A1 Reagents and methods for identification of binding agents |
| 01/17/2002 | CA2415808A1 Transporters and ion channels |
| 01/17/2002 | CA2415544A1 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/17/2002 | CA2415484A1 Human myeloma cell line |
| 01/17/2002 | CA2415434A1 Use of the heat shock protein gp96 |
| 01/17/2002 | CA2415422A1 Chromosome 3p21.3 genes are tumor suppressors |
| 01/17/2002 | CA2415124A1 Use of a liquid medicament in surgical high pressure liquid jet devices |
| 01/17/2002 | CA2415100A1 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
| 01/17/2002 | CA2415086A1 7,8 and 9-substituted tetracycline compounds |
| 01/17/2002 | CA2415083A1 Anti-hiv and anti-tumor peptides and fragments of lysozyme |
| 01/17/2002 | CA2415052A1 Combinations of bisphosphonates, estrogenic agents and optionally estrogens |
| 01/17/2002 | CA2414926A1 Microspheres and adjuvants for dna vaccine delivery |
| 01/17/2002 | CA2414480A1 Fatty acid analogues for the treatment of cancer |
| 01/17/2002 | CA2414387A1 Drug metabolizing enzymes |
| 01/17/2002 | CA2414219A1 Lipid metabolism molecules |
| 01/17/2002 | CA2413810A1 Aminoacyl trna synthetases |
| 01/17/2002 | CA2412162A1 Chemokine receptor modulators, production and use |
| 01/17/2002 | CA2412150A1 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
| 01/17/2002 | CA2411160A1 Colchinol derivatives as vascular damaging agents |
| 01/17/2002 | CA2405798A1 Pyrido¬2,3-d|pyrimidine and pyrimido¬4,5-d|pyrimidine nucleosides |
| 01/16/2002 | EP1172654A1 Diagnostic method based on the detection of the L1 adhesion molecule for ovarian and endometrial tumors |
| 01/16/2002 | EP1172386A1 Functionalized glycosaminoglycan polymer and medical instruments and drugs by using the same |
| 01/16/2002 | EP1172361A1 Sulfonamide derivatives having oxadiazole rings |
| 01/16/2002 | EP1172110A2 Use of lipoic acid as a bioavailaty enhancer of mineral salts |
| 01/16/2002 | EP1172107A1 Drugs containing sulfopyranosylacylglycerol derivatives |
| 01/16/2002 | EP1171626A1 50 human secreted proteins |
| 01/16/2002 | EP1171614A1 Dsp-4 dual-specificity map kinase phosphatase |
| 01/16/2002 | EP1171613A1 Dsp-7 dual-specificity map kinase phosphatase |
| 01/16/2002 | EP1171612A2 Telomerase-specific cancer vaccine |